Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. - Wikidata - wikimedia - TriplyDB

Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.

Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.

http://www.wikidata.org/entity/Q44333056

about

Therapy Insight: AIDS-related malignancies—the influence of antiviral therapy on pathogenesis and management Interventions for previously untreated patients with AIDS-associated Non-Hodgkin´s Lymphoma How I treat HIV-associated lymphoma Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium.Study on effectiveness of gemcitabine, dexamethasone, and cisplatin (GDP) for relapsed or refractory AIDS-related non-Hodgkin's lymphoma.Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma.Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034 Plasmablastic lymphoma in a previously undiagnosed AIDS patient: a case report.A case of complete heart block reverting to normal sinus rhythm after treatment for cardiac invasive Burkitt's lymphoma.Newly emerging therapies targeting viral-related lymphomas.The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy Zidovudine-based lytic-inducing chemotherapy for Epstein-Barr virus-related lymphomas.Blood and marrow transplant for lymphoma patients with HIV/AIDS.Primary pulmonary lymphoma in a patient with advanced AIDS How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus.Treatment options of AIDS-related lymphoma.A comparative study of molecular characteristics of diffuse large B-cell lymphoma from patients with and without human immunodeficiency virus infection.Should HIV-positive patients with lymphoma be offered stem cell transplants?AIDS-Related Non-Hodgkin's Lymphoma in the Era of Highly Active Antiretroviral Therapy AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma.B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis.Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges.Adult T cell leukemia lymphoma.Paradigms and Controversies in the Treatment of HIV-Related Burkitt Lymphoma.Use of antineoplastic agents in patients with cancer who have HIV/AIDS.AIDS-related cancer in the era of highly active antiretroviral therapy (HAART): a model of the interplay of the immune system, virus, and cancer. "On the offensive--the Trojan Horse is being destroyed"--Part B: Malignant lymphoma.Optimal management of cervical cancer in HIV-positive patients: a systematic review.Radiotherapy for patients with the human immunodeficiency virus: are special precautions necessary?Controversies in the treatment of Burkitt lymphoma in AIDS Human T cell lymphotropic virus-associated leukemia/lymphoma Management of patients with HIV in the intensive care unit Non-Hodgkin's lymphoma and the CNS: prophylaxis and therapy in immunocompetent and HIV-positive individuals.Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047 AIDS, T cells, chemotherapy: HAART-breaking?Oncologic complications of human immunodeficiency virus infection: changing epidemiology, treatments, and special considerations in the era of highly active antiretroviral therapy.Modern management of non-Hodgkin lymphoma in HIV-infected patients.

P2860

Q22251070-5AA12430-DFAB-448E-83BF-336AEB0A3E17 Q24240190-1431C75E-772D-4029-BA43-58B00F277EED Q26821860-C07D49F4-ADE2-4948-8145-D9EDFCDC0B04 Q33401481-325908D2-D996-44DB-AD8C-C82E56497D7B Q33402306-7B164B3C-6201-4558-ABBC-BE4B532C03AE Q33407197-0F44E3CE-2A6F-4F25-928F-40433FB65B3C Q33561185-E0FBF040-7416-45AE-8A4B-A172051014D9 Q33594875-BD14F6D6-1B87-4023-95C1-11BEFAD19C57 Q33653527-363D7749-1E25-497E-A4A3-4BE5F0545963 Q33699201-6C78EE81-1887-482D-A320-3BD95BD3C2EB Q33805988-E5C72647-4BBF-4DD9-B313-B8EB3EBBE5F6 Q33806007-93521E0F-F3F3-4716-9576-107FDA36E7E8 Q33952616-0FEA8AEF-47ED-4E04-9AC9-6CE40C32C67E Q34053519-9504F480-6F7A-4011-BF86-2E78CC7AE80C Q34068528-DBF891F0-CF24-4996-993F-9CCB47B67AEA Q34768232-C2267B85-AD58-4D05-977F-795712C32045 Q35103531-DB20A8F0-0FEC-440B-9827-F904356BB7A6 Q35183751-DDBA26EA-D6F6-40D0-A4AF-C894CF7338D8 Q35230899-6105A499-2066-4CA5-92B9-0A17142EBE4B Q35547755-F58338BC-0EAF-454E-ABC2-61015AF14F57 Q35779619-9F6C33D4-B769-4C5E-9889-85BD05E3B8B8 Q35836856-1A8B048F-B3F7-4DA8-9434-2C9DFEBC4C84 Q35847948-5FD54DCD-F65C-4E35-8014-5348679E11EC Q35848116-DC23AAE6-69E3-4465-B2DC-D744E60375A1 Q35848330-3909D73E-87A7-4BCD-9022-26727692BF9B Q35850380-8F1FBBA3-2070-4CA8-A549-07CDD079AFC5 Q35880693-4FB62786-524E-4504-AF69-F2B65E4D0E3A Q35915375-5C04F662-83A8-43DA-B01C-D7CD6A45D0DC Q35932561-50573383-2ED4-48F8-904E-4756A234743D Q35973889-8E34DD26-B7BE-4555-B543-A60819168671 Q36051789-7623AA57-ADD3-4DCB-B1D8-0ABF47409A1D Q36132370-0A5864B1-5E46-4DA0-BC40-C5E24B40B8E1 Q36151295-A203DFDC-AED8-44A2-8C9A-233C20C543E5 Q36225607-4CB38C7B-F5D4-44E5-972F-4AE2DDC5A101 Q36403151-1D95D239-B6ED-4F37-B9BB-4D2F819B416C Q36407441-33D3EAE7-92FC-41ED-845C-99C3C2603F84 Q36490052-7AC0504B-D70B-40FA-B572-2A4E2FD02FB3 Q36528722-0F8CBEE4-BCAF-480E-9F15-546A5BFECD83 Q36693871-16198967-26F9-43E6-9F1E-AED563800B0C Q36710347-AAF0A2EE-5C74-484D-98CC-D95A5A3C2D2F

P2860

Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.

http://www.wikidata.org/entity/Q44333056

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Highly effective treatment of ...... suspension and tumor biology.

@en

Highly effective treatment of ...... suspension and tumor biology.

@nl

type

label

Highly effective treatment of ...... suspension and tumor biology.

@en

Highly effective treatment of ...... suspension and tumor biology.

@nl

prefLabel

Highly effective treatment of ...... suspension and tumor biology.

@en

Highly effective treatment of ...... suspension and tumor biology.

@nl

P1433

Q44333056-4726D343-B111-4801-8DA3-2ADB39E46461

P1476

Q44333056-DDBC5B21-86A0-4BD3-9279-3AE9082178CC

P2093

Q44333056-11B7F552-6379-4C1C-887E-5C6B59AB3619

Q44333056-1A27C481-C0E0-48E2-BB43-5064AA42DD4B

Q44333056-1EA81385-52D9-4541-BB5B-44CE8D80F399

Q44333056-1F534B63-124E-4C75-8813-46A3319E27AB

Q44333056-49A1998B-1E55-4C50-95EF-84CB633FFA27

Q44333056-733C8052-A83A-4720-A09A-7103022B72A1

Q44333056-AD953E25-A3FC-4D5E-BCC4-BB8B3AA94FFE

Q44333056-B621BAC0-1EB0-4117-955F-F3A5BEDEAA09

Q44333056-B81A3DD3-BFA2-4C2A-99AF-4CA82E48152A

Q44333056-C0B7EC75-C7FE-4672-912C-CF8CF710F1AD

P304

Q44333056-CA602F98-645B-4731-9DF2-3462D148FC2D

P31

Q44333056-AFDB8355-CAD6-4766-BF2C-84085935392D

P356

Q44333056-00A18DF9-4147-49CC-8AF0-BCD0E26126C6

P407

Q44333056-95F84014-AEF9-4C6A-8BDB-F1DDF0B6F688

P433

Q44333056-F738689E-09CC-4712-815E-2F749F87A33F

P478

Q44333056-D54D8977-6882-47FE-844E-A6CAEF4C42C7

P577

Q44333056-F48D32D8-6298-4B0A-91E7-72A76CF75020

P698

Q44333056-5854C1A9-CDD2-45B6-8180-53354DDB7528

P356

BLOOD-2002-11-3589

P1433

P1476

Highly effective treatment of ...... suspension and tumor biology.

@en

P2093

Elaine S Jaffe

http://www.w3.org/2001/XMLSchema#string

Gene Shearer

http://www.w3.org/2001/XMLSchema#string

Genoveffa Franchini

http://www.w3.org/2001/XMLSchema#string

Hiroaki Mitsuya

http://www.w3.org/2001/XMLSchema#string

Mark F Kavlick

http://www.w3.org/2001/XMLSchema#string

Mark Raffeld

http://www.w3.org/2001/XMLSchema#string

Martin Gutierrez

http://www.w3.org/2001/XMLSchema#string

Nicole Grant

http://www.w3.org/2001/XMLSchema#string

Richard F Little

http://www.w3.org/2001/XMLSchema#string

Robert Yarchoan

http://www.w3.org/2001/XMLSchema#string

P304

4653-4659

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2002-11-3589

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P577

2003-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12609827

http://www.w3.org/2001/XMLSchema#string